West Pharmaceutical and Corning form landmark injectable drug delivery collaboration
The collaboration includes a multimillion-dollar investment to expand glass technology that will advance packaging and delivery systems
West Pharmaceutical Services and Corning have pooled their areas of expertise in a collaboration designed to advance patient safety and expand access to treatments.
By harnessing West's experience in injectable drug solutions and Corning's materials science expertise, the companies intend to enable advanced injectable drug packaging and delivery systems for the pharmaceutical industry.
Specifically, the collaboration, which includes the support of a multimillion-dollar investment, will combine West's NovaPure components with Daikyo Flurotec coating technology, and Corning's Valor Glass and Velocity Vials to provide innovative pharmaceutical packaging solutions to help bio-pharma producers navigate the complex regulatory environment and mitigate risk in bringing drugs to market.
Corning's Valor Glass can enable increased throughput and offers high chemical durability, strength, and damage resistance, thereby enhancing the storage and delivery of drugs ... which in turn, means more reliable access to essential modern medicines.
Wendell P. Weeks, Chairman and Chief Executive Officer, Corning, described the collaboration and the combined technology as a "win-win for customers and patients all over the world".
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.